5:44 PM · 21 September 2022

Sesen Bio slumps 35% on merger news

Sesen Bio (SESN.US), late-stage clinical company, is one of the worst performing stocks on Wall Street today. Share price plunges around 35% following announcement of merger agreement between Sesen Bio and Carisma Therapeutics, a closely-held US biotechnology company. Merger will be an all-stock deal with current Sesen shareholders owning 41.7% of the combined entity and current Carisma shareholders owning the other 58.3%. Deal was unanimously approved by boards of both companies and is expected to close in 3-4 months. A new company will operate as Carisma Therapeutics and will be listed on NASDAQ exchange under ticker CARM.

Share price of Sesen Bio (SESN.US) slumped following news of merger with private company Carisma Therapeutics. Stock is down 35% today and trades at the lowest level since mid-May 2022. Source: xStation5

22 September 2026, 6:40 PM

Daily Summary: Trump’s UN Speech Puts Iran, Hormuz and AI in the Spotlight

22 September 2026, 6:13 PM

AWS Gets NATO Approval. Opening the Door to More Defense Contracts

22 September 2026, 4:31 PM

AMD Surpasses One Trillion Dollars in Market Capitalization. Now Wall Street Is Raising the Bar

22 September 2026, 2:58 PM

US OPEN: Tech is looking for a reason to grow, diplomacy in the background

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits